Form 4: Bone Biologics Director Phillip Meikle II Receives New Stock Option Grant

Bone Biologics Corp. Director Phillip Meikle II was granted 62,894 non-employee stock options at an exercise price of $0.88, vesting quarterly over one year.

Summary

• Phillip Terry Meikle II, a Director of Bone Biologics Corp. (BBLG), reported a change in beneficial ownership via a Form 4 filing.
• On June 4, 2025, Mr. Meikle was granted 62,894 non-employee stock options under the Bone Biologics Corporation 2015 Equity Incentive Plan.
• These newly granted options have an exercise price of $0.88 per share and an expiration date of June 4, 2035.
• The 62,894 options are set to vest in four equal quarterly installments.
• Following this transaction, Mr. Meikle beneficially owns a total of 91,088 derivative securities, comprising the newly acquired options and previously held options.
• His total beneficial ownership includes 28,185 non-employee stock options granted on October 16, 2024, with an exercise price of $1.88, which vest in equal installments on December 17, 2024, March 19, 2025, June 19, 2025, and September 17, 2025.
• Additionally, he holds 9 fully exercisable non-employee stock options from October 16, 2024, also with an exercise price of $1.88.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive signal for aligning management and shareholder interests, but it is a routine compensation event rather than a major operational or financial announcement that would significantly alter the company's outlook.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options are granted under an existing equity incentive plan (Bone Biologics Corporation 2015 Equity Incentive Plan), indicating a structured approach to executive compensation.

Negatives

• The exercise price of $0.88 for the newly granted options is lower than the $1.88 exercise price of previously granted options, which could suggest a lower perceived value of the stock at the time of the new grant or a more favorable compensation term for the director.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's beneficial ownership change.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape within the biologics or medical device sector.

Corporate Governance

Related Party Transactions

• The grant of 62,894 non-employee stock options to Phillip Terry Meikle II, a Director of Bone Biologics Corp., constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive for shareholders as it aligns the director's financial interests with the company's long-term stock performance.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The newly granted 62,894 options will vest in four equal quarterly installments, leading to future exercisability for the director.

Key Dates

Recommendation

Keywords

Bone Biologics Corp, BBLG, SEC Form 4, stock options, beneficial ownership, director compensation, equity incentive plan, insider transaction